二线治疗-话题@MedSci

#二线治疗#

120篇内容 | 3384人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1543927, encodeId=47a9154392e94, content=<a href='/topic/show?id=02982402298' target=_blank style='color:#2F92EE;'>#二线治疗#</a>, objectTitle=BMJ：糖尿病患者接受磺脲类二线治疗需警惕心血管及严重低血糖事件, objectType=article, longId=144836, objectId=b375144836ce, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b375144836ce, replyNumber=0, likeNumber=83, createdTime=2018-07-22, rootId=0, userName=ms5768352621950538, userId=520213623738, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b375144836ce, moduleTitle=BMJ：糖尿病患者接受磺脲类二线治疗需警惕心血管及严重低血糖事件, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b375144836ce)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1543926, encodeId=afe71543926f7, content=<a href='/topic/show?id=02982402298' target=_blank style='color:#2F92EE;'>#二线治疗#</a>, objectTitle=Lancet Oncol：双雄相争谁才是转移性结直肠癌的更佳二线治疗？, objectType=article, longId=140357, objectId=74a314035e50, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=74a314035e50, replyNumber=0, likeNumber=58, createdTime=2018-06-10, rootId=0, userName=ms5768352621950538, userId=520213623738, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=74a314035e50, moduleTitle=Lancet Oncol：双雄相争谁才是转移性结直肠癌的更佳二线治疗？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=74a314035e50)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1543925, encodeId=e1c615439255f, content=<a href='/topic/show?id=02982402298' target=_blank style='color:#2F92EE;'>#二线治疗#</a>, objectTitle=Ann Oncol：口服紫杉醇二线治疗晚期胃癌是否有效？, objectType=article, longId=140231, objectId=0bac1402313a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0bac1402313a, replyNumber=0, likeNumber=54, createdTime=2018-06-09, rootId=0, userName=ms5768352621950538, userId=520213623738, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0bac1402313a, moduleTitle=Ann Oncol：口服紫杉醇二线治疗晚期胃癌是否有效？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0bac1402313a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1543924, encodeId=4ff015439240c, content=<a href='/topic/show?id=02982402298' target=_blank style='color:#2F92EE;'>#二线治疗#</a>, objectTitle=Lancet：派姆单抗单药二线治疗胃以及胃食管交界癌效果不佳, objectType=article, longId=140045, objectId=0720140045ca, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0720140045ca, replyNumber=0, likeNumber=66, createdTime=2018-06-07, rootId=0, userName=ms5768352621950538, userId=520213623738, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0720140045ca, moduleTitle=Lancet：派姆单抗单药二线治疗胃以及胃食管交界癌效果不佳, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0720140045ca)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1543923, encodeId=9998154392312, content=<a href='/topic/show?id=02982402298' target=_blank style='color:#2F92EE;'>#二线治疗#</a>, objectTitle=蔡真教授：多发性骨髓瘤二线治疗的新药方案及治疗策略选择, objectType=article, longId=139020, objectId=9ba513902018, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9ba513902018, replyNumber=0, likeNumber=0, createdTime=2018-05-26, rootId=0, userName=ms5768352621950538, userId=520213623738, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9ba513902018, moduleTitle=蔡真教授：多发性骨髓瘤二线治疗的新药方案及治疗策略选择, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9ba513902018)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1543922, encodeId=495d154392224, content=<a href='/topic/show?id=02982402298' target=_blank style='color:#2F92EE;'>#二线治疗#</a>, objectTitle=J Infect：中国多药耐药肺结核患者：标准二线治疗方案有多大作用？, objectType=article, longId=138500, objectId=a457138500ff, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a457138500ff, replyNumber=0, likeNumber=104, createdTime=2018-05-20, rootId=0, userName=ms5768352621950538, userId=520213623738, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a457138500ff, moduleTitle=J Infect：中国多药耐药肺结核患者：标准二线治疗方案有多大作用？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a457138500ff)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1543921, encodeId=d3661543921fb, content=<a href='/topic/show?id=02982402298' target=_blank style='color:#2F92EE;'>#二线治疗#</a>, objectTitle=JAMA Oncol：免疫检查点抑制剂二线治疗NSCLC预后因素Meta分析, objectType=article, longId=129875, objectId=555c1298e5f2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=555c1298e5f2, replyNumber=0, likeNumber=133, createdTime=2018-02-15, rootId=0, userName=ms5768352621950538, userId=520213623738, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=555c1298e5f2, moduleTitle=JAMA Oncol：免疫检查点抑制剂二线治疗NSCLC预后因素Meta分析, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=555c1298e5f2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1543920, encodeId=11291543920d3, content=<a href='/topic/show?id=02982402298' target=_blank style='color:#2F92EE;'>#二线治疗#</a>, objectTitle=JCO：IMPRESS研究解读：吉非替尼耐药后二线治疗该如何选择？, objectType=article, longId=125909, objectId=6db01259095c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6db01259095c, replyNumber=0, likeNumber=54, createdTime=2018-01-09, rootId=0, userName=ms5768352621950538, userId=520213623738, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6db01259095c, moduleTitle=JCO：IMPRESS研究解读：吉非替尼耐药后二线治疗该如何选择？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6db01259095c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1543919, encodeId=33d915439194d, content=<a href='/topic/show?id=02982402298' target=_blank style='color:#2F92EE;'>#二线治疗#</a>, objectTitle=Diabetes Care：抗高血糖药物：开始二线治疗前一线药物的使用情况如何？, objectType=article, longId=125080, objectId=bd8012508026, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bd8012508026, replyNumber=0, likeNumber=68, createdTime=2017-12-31, rootId=0, userName=ms5768352621950538, userId=520213623738, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bd8012508026, moduleTitle=Diabetes Care：抗高血糖药物：开始二线治疗前一线药物的使用情况如何？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bd8012508026)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1543918, encodeId=1a2115439183e, content=<a href='/topic/show?id=02982402298' target=_blank style='color:#2F92EE;'>#二线治疗#</a>, objectTitle=Clin Gastroenterol H：自身免疫性肝炎二线治疗：吗替麦考酚酯vs他克莫司, objectType=article, longId=125079, objectId=39431250e904, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=39431250e904, replyNumber=0, likeNumber=56, createdTime=2017-12-31, rootId=0, userName=ms5768352621950538, userId=520213623738, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=39431250e904, moduleTitle=Clin Gastroenterol H：自身免疫性肝炎二线治疗：吗替麦考酚酯vs他克莫司, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=39431250e904)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1543917, encodeId=8098154391eb7, content=<a href='/topic/show?id=02982402298' target=_blank style='color:#2F92EE;'>#二线治疗#</a>, objectTitle=Aliment Pharmacol Ther：来那度胺作为晚期肝细胞癌的二线治疗显示出中度活性, objectType=article, longId=116512, objectId=93301165126f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=93301165126f, replyNumber=0, likeNumber=99, createdTime=2017-10-19, rootId=0, userName=ms5768352621950538, userId=520213623738, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=93301165126f, moduleTitle=Aliment Pharmacol Ther：来那度胺作为晚期肝细胞癌的二线治疗显示出中度活性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=93301165126f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1543916, encodeId=c36b15439165f, content=<a href='/topic/show?id=02982402298' target=_blank style='color:#2F92EE;'>#二线治疗#</a>, objectTitle=CSCO:晚期NSCLC二线治疗研究进展, objectType=article, longId=113965, objectId=9cfe11396502, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9cfe11396502, replyNumber=0, likeNumber=59, createdTime=2017-09-25, rootId=0, userName=ms5768352621950538, userId=520213623738, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9cfe11396502, moduleTitle=CSCO:晚期NSCLC二线治疗研究进展, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9cfe11396502)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1543915, encodeId=f46a154391500, content=<a href='/topic/show?id=02982402298' target=_blank style='color:#2F92EE;'>#二线治疗#</a>, objectTitle=Ann Oncol：免疫检查点抑制剂对NSCLC的二线治疗的成本效益和经济影响如何？, objectType=article, longId=111168, objectId=7211111168c3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7211111168c3, replyNumber=0, likeNumber=68, createdTime=2017-08-30, rootId=0, userName=ms5768352621950538, userId=520213623738, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7211111168c3, moduleTitle=Ann Oncol：免疫检查点抑制剂对NSCLC的二线治疗的成本效益和经济影响如何？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7211111168c3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1543914, encodeId=765d15439148b, content=<a href='/topic/show?id=02982402298' target=_blank style='color:#2F92EE;'>#二线治疗#</a>, objectTitle=Br J Haematol：利妥昔单抗二线治疗儿童AIHA的获益及风险, objectType=article, longId=105909, objectId=dff410590995, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=dff410590995, replyNumber=0, likeNumber=134, createdTime=2017-07-20, rootId=0, userName=ms5768352621950538, userId=520213623738, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=dff410590995, moduleTitle=Br J Haematol：利妥昔单抗二线治疗儿童AIHA的获益及风险, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=dff410590995)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1543913, encodeId=43e615439138c, content=<a href='/topic/show?id=02982402298' target=_blank style='color:#2F92EE;'>#二线治疗#</a>, objectTitle=肺癌二线治疗失败、耐药后，何去何从？, objectType=article, longId=100432, objectId=4ccb100432fe, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4ccb100432fe, replyNumber=0, likeNumber=74, createdTime=2017-06-03, rootId=0, userName=ms5768352621950538, userId=520213623738, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4ccb100432fe, moduleTitle=肺癌二线治疗失败、耐药后，何去何从？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4ccb100432fe)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1543912, encodeId=cae8154391240, content=<a href='/topic/show?id=02982402298' target=_blank style='color:#2F92EE;'>#二线治疗#</a>, objectTitle=JCO：Brigatinib二线治疗ALK阳性NSCLC有力量, objectType=article, longId=98708, objectId=105298e082a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=105298e082a, replyNumber=0, likeNumber=42, createdTime=2017-05-16, rootId=0, userName=ms5768352621950538, userId=520213623738, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=105298e082a, moduleTitle=JCO：Brigatinib二线治疗ALK阳性NSCLC有力量, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=105298e082a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1543911, encodeId=26971543911cc, content=<a href='/topic/show?id=02982402298' target=_blank style='color:#2F92EE;'>#二线治疗#</a>, objectTitle=Arthritis Rheumatol：多生物标志物疾病活动评分和MTX治疗失败后早期类风湿关节炎的二线治疗选择, objectType=article, longId=97445, objectId=ca789e44586, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ca789e44586, replyNumber=0, likeNumber=94, createdTime=2017-04-30, rootId=0, userName=ms5768352621950538, userId=520213623738, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ca789e44586, moduleTitle=Arthritis Rheumatol：多生物标志物疾病活动评分和MTX治疗失败后早期类风湿关节炎的二线治疗选择, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ca789e44586)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1543910, encodeId=1d75154391017, content=<a href='/topic/show?id=02982402298' target=_blank style='color:#2F92EE;'>#二线治疗#</a>, objectTitle=NEJM：Pembrolizumab二线治疗尿路上皮癌优于化疗（KEYNOTE-045）, objectType=article, longId=92485, objectId=2590924851f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2590924851f, replyNumber=0, likeNumber=70, createdTime=2017-03-21, rootId=0, userName=ms5768352621950538, userId=520213623738, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2590924851f, moduleTitle=NEJM：Pembrolizumab二线治疗尿路上皮癌优于化疗（KEYNOTE-045）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2590924851f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1543909, encodeId=4181154390917, content=<a href='/topic/show?id=02982402298' target=_blank style='color:#2F92EE;'>#二线治疗#</a>, objectTitle=NEJM：Pembrolizumab作为晚期尿路上皮癌二线治疗疗效如何？, objectType=article, longId=89310, objectId=b04a893104a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b04a893104a, replyNumber=0, likeNumber=0, createdTime=2017-02-20, rootId=0, userName=ms5768352621950538, userId=520213623738, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b04a893104a, moduleTitle=NEJM：Pembrolizumab作为晚期尿路上皮癌二线治疗疗效如何？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b04a893104a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1543908, encodeId=da8a15439089e, content=<a href='/topic/show?id=02982402298' target=_blank style='color:#2F92EE;'>#二线治疗#</a>, objectTitle=肝癌福音！美国FDA授予拜耳靶向抗癌药Stivarga优先审查资格，二线治疗晚期肝细胞癌, objectType=article, longId=86806, objectId=74ba86806dc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=74ba86806dc, replyNumber=0, likeNumber=55, createdTime=2017-01-07, rootId=0, userName=ms5768352621950538, userId=520213623738, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=74ba86806dc, moduleTitle=肝癌福音！美国FDA授予拜耳靶向抗癌药Stivarga优先审查资格，二线治疗晚期肝细胞癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=74ba86806dc)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

二线治疗

2020-05-29

ms5768352621950538 (审核中...)

前往app查看评论内容

#二线治疗#

BMJ：糖尿病患者接受磺脲类二线治疗需警惕心血管及严重低血糖事件

2018-07-22

ms5768352621950538 (审核中...)

前往app查看评论内容

#二线治疗#

Lancet Oncol：双雄相争谁才是转移性结直肠癌的更佳二线治疗？

2018-06-10

ms5768352621950538 (审核中...)

前往app查看评论内容

#二线治疗#

Ann Oncol：口服紫杉醇二线治疗晚期胃癌是否有效？

2018-06-09

ms5768352621950538 (审核中...)

前往app查看评论内容

#二线治疗#

Lancet：派姆单抗单药二线治疗胃以及胃食管交界癌效果不佳

2018-06-07

ms5768352621950538 (审核中...)

前往app查看评论内容

#二线治疗#

蔡真教授：多发性骨髓瘤二线治疗的新药方案及治疗策略选择

2018-05-26

ms5768352621950538 (审核中...)

前往app查看评论内容

#二线治疗#

J Infect：中国多药耐药肺结核患者：标准二线治疗方案有多大作用？

2018-05-20

ms5768352621950538 (审核中...)

前往app查看评论内容

#二线治疗#

JAMA Oncol：免疫检查点抑制剂二线治疗NSCLC预后因素Meta分析

2018-02-15

ms5768352621950538 (审核中...)

前往app查看评论内容

#二线治疗#

JCO：IMPRESS研究解读：吉非替尼耐药后二线治疗该如何选择？

2018-01-09

ms5768352621950538 (审核中...)

前往app查看评论内容

#二线治疗#

Diabetes Care：抗高血糖药物：开始二线治疗前一线药物的使用情况如何？

2017-12-31

ms5768352621950538 (审核中...)

前往app查看评论内容

#二线治疗#

Clin Gastroenterol H：自身免疫性肝炎二线治疗：吗替麦考酚酯vs他克莫司

2017-12-31

ms5768352621950538 (审核中...)

前往app查看评论内容

#二线治疗#

Aliment Pharmacol Ther：来那度胺作为晚期肝细胞癌的二线治疗显示出中度活性

2017-10-19

ms5768352621950538 (审核中...)

前往app查看评论内容

#二线治疗#

CSCO:晚期NSCLC二线治疗研究进展

2017-09-25

ms5768352621950538 (审核中...)

前往app查看评论内容

#二线治疗#

Ann Oncol：免疫检查点抑制剂对NSCLC的二线治疗的成本效益和经济影响如何？

2017-08-30

ms5768352621950538 (审核中...)

前往app查看评论内容

#二线治疗#

Br J Haematol：利妥昔单抗二线治疗儿童AIHA的获益及风险

2017-07-20

ms5768352621950538 (审核中...)

前往app查看评论内容

#二线治疗#

肺癌二线治疗失败、耐药后，何去何从？

2017-06-03

ms5768352621950538 (审核中...)

前往app查看评论内容

#二线治疗#

JCO：Brigatinib二线治疗ALK阳性NSCLC有力量

2017-05-16

ms5768352621950538 (审核中...)

前往app查看评论内容

#二线治疗#

Arthritis Rheumatol：多生物标志物疾病活动评分和MTX治疗失败后早期类风湿关节炎的二线治疗选择

2017-04-30

ms5768352621950538 (审核中...)

前往app查看评论内容

#二线治疗#

NEJM：Pembrolizumab二线治疗尿路上皮癌优于化疗（KEYNOTE-045）

2017-03-21

ms5768352621950538 (审核中...)

前往app查看评论内容

#二线治疗#

NEJM：Pembrolizumab作为晚期尿路上皮癌二线治疗疗效如何？

2017-02-20

ms5768352621950538 (审核中...)

前往app查看评论内容

#二线治疗#

肝癌福音！美国FDA授予拜耳靶向抗癌药Stivarga优先审查资格，二线治疗晚期肝细胞癌

2017-01-07

科室
- - 订阅+
  - 更多科室
工具
服务